Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7520934 | 0.82 | NPC1 (0.62) | POLBKMT2ASMN1; SMN2MAPT | |
| Methyl 3,5-Dinitrobenzoate SCHEMBL418416 | 0.82 | SMN1; SMN2 (0.60) | POLBMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL561284 | 0.82 | HTT (0.64) | POLBMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL300172 | 0.81 | CA1 (0.52) | POLBMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL7525861 | 0.79 | CYP3A4 (0.42) | MEN1KMT2ASMN1; SMN2MAPTALOX5 | |
| SCHEMBL7406647 | 0.78 | TP53 (0.56) | MEN1KMT2ASMN1; SMN2ALOX5 | |
| SCHEMBL8413415 | 0.77 | HTT (0.56) | POLBMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL8762477 | 0.77 | HTT (0.59) | POLBMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL16952347 | 0.77 | CYP3A4 (0.66) | POLBMEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL3082334 | 0.76 | TSHR (0.57) | POLBMEN1KMT2AHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139546-B2 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2015-09-22 | — | — | US | claimed |
| US-20110207748-A1 | Tri-Aryl/Heteroaromatic Cannabinoids and Use Thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2011-08-25 | — | — | US | claimed |
| US-7888365-B2 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2011-02-15 | — | — | US | claimed |
| EP-2131655-A2 | TRI-ARYL/HETEROAROMATIC CANNABINOIDS AND USE THEREOF | The University of Tennessee Research Foundation (US) | 2009-12-16 | — | — | EP | claimed |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-09-25 | — | — | US | claimed |
| WO-2008109027-A2 | TRI-ARYL/HETEROAROAROMATIC CANNABINOIDS AND USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) | 2008-09-12 | — | — | WO | claimed |
| CN-115279741-A | 4-phenyl-N- (phenyl) thiazol-2-amine derivatives and related compounds as Aryl Hydrocarbon Receptor (AHR) agonists for the treatment of, for example, angiogenesis-related disorders or inflammatory disorders | 医肯纳肿瘤学公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-111108148-B | Treatment additives for silicone elastomer bases | 美国陶氏有机硅公司 | 2022-08-23 | — | — | CN | disclosed |
| US-20210087360-A1 | HANDLING ADDITIVE FOR SILICONE ELASTOMER BASES | DOW SILICONES CORPORATION | 2021-03-25 | — | — | US | disclosed |
| EP-3662012-A1 | HANDLING ADDITIVE FOR SILICONE ELASTOMER BASES | Dow Silicones Corporation (US) | 2020-06-10 | — | — | EP | disclosed |
| CN-111108148-A | Treatment additives for silicone elastomer bases | 美国陶氏有机硅公司 | 2020-05-05 | — | — | CN | disclosed |
| EP-2900645-B1 | HERBICIDAL AND FUNGICIDAL 3-PHENYLISOXAZOLIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| WO-2019024779-A1 | HANDLING ADDITIVE FOR SILICONE ELASTOMER BASES | DOW SILICONES CORPORATION (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-0934937-A1 | Azole derivatives as superoxide radical inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| EP-0920426-A1 | NEW THIAZOLE DERIVATIVES WITH PHOSPHODIESTERASE-INHIBITING EFFECT | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998008841-A1 | NEW THIAZOLE DERIVATIVES WITH PHOSPHODIESTERASE-INHIBITING EFFECT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-03-05 | — | — | WO | disclosed |
| WO-1998008830-A1 | THIAZOLE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE-IV | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-03-05 | — | — | WO | disclosed |
| US-5677319-A | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5643932-A | PREVENTS CELL DAMAGE AFTER ISCHEMIA AND RE-PERFUSION, SUBSTITUTED THIAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0513387-A1 | ACTIVE OXYGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | CNR1, CNR2, OPRM1 | POLB 4171/4885MEN1 3801/4885KMT2A 2313/4885 |
| US-20110207748-A1 | Tri-Aryl/Heteroaromatic Cannabinoids and Use Thereof | CNR1, CNR2, OPRM1 | POLB 4171/4885MEN1 3801/4885KMT2A 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.